Fewer retreatments with combination AMD therapy

Article

Providing patients with renewed hope and the chance of halting and maybe even reversing vision loss, the launch of this anti-VEGF therapy has signalled a permanent change in the way this debilitating disorder is treated worldwide.

Key Points

Study data in support of this class of drugs has been compelling; however, the dosing and follow-up regimen associated with anti-VEGF therapy and the fact that almost all subtypes of AMD are now treatable has raised several practice management problems.

Research therefore continues to find the optimum therapeutic approach to AMD therapy, which benefits from the chronic neovascularization (CNV) inhibition properties of anti-VEGF agents, and also uses the traditional therapeutic approaches to complement VEGF inhibition, whilst reducing treatment and follow-up frequency.

Speaking at the 7th International AMD Congress in Marbella, Spain, during October 2007, Dr Henry L. Hudson of Retina Centers PC in Tucson, Arizona, US discussed a study that he has been involved in, which aims to assess the effectiveness of the combination approach.

Registry of AMD therapy: Visudyne + anti-VEGF

This particular study captures data from a Registry, which was initiated in 2005 and holds information for 1195 patients with either predominantly classic lesions (46%), minimally classic lesions (31%) and no classic CNV (23%). The mean age of patients was 79.2 years and twelve-month follow-up data was available for 587 eyes (almost 50% of study participants).

In this study, the vast majority of patients were treated with the anti-VEGF bevacizumab (Avastin) administered within 14 days of Visudyne treatment. At least three-month follow-up data is available for 1?048 patients, who were segmented into one of three categories: 1) same day Visudyne + bevacizumab treatment (n=366); 2) Visudyne first (n=247); 3) bevacizumab first (n=435).

"Participation in the Registry was voluntary. Most importantly, there's an adverse events recording form, which is compulsory, unlike the original bevacizumab registry, which has been reported by others," assured Dr Hudson.

Vision benefits in all patients

"The overall vision benefit of combining anti-VEGF therapy with PDT was proven without a doubt," confirmed Dr Hudson. Based on the study results, there was a mean gain of around seven letters in the combination treatment arm, which had declined slightly by one-year follow-up.

"Of note, it takes about 4.1 months to require an additional injection of bevacizumab and 5.7 months to the next PDT session," added Dr Hudson.

When comparing treatment-naïve versus previously treated lesions, the mean vision improvement was even more marked: an eight to nine letter gain in treatment-naïve patients.

"With regards to the previously treated lesions, many were very old, and had received multiple anti-VEGF injections, previous combination therapies, you name it, and yet visual acuity gains were still seen," emphasized Dr Hudson.

Even in this group of patients, the time interval between bevacizumab injections was 3.8 to 4.4 months and five to six months to the next PDT, with nearly a third of patients requiring no retreatment at all.

A benefit was also noticeable in the same day treatment group. Although Dr Hudson concedes that this group may have contained more treatment-naïve patients than the others, thus exemplifying the benefit of same day treatment, a positive effect was seen nonetheless. "Interestingly, one sees visual benefit regardless of whether the anti-VEGF agent is given first, together or second," said Dr Hudson.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
© 2025 MJH Life Sciences

All rights reserved.